دورية أكاديمية
Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993.
| العنوان: | Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993. |
|---|---|
| المؤلفون: | Emens, L.A.1 (AUTHOR) emensla@upmc.edu, Adams, S.2 (AUTHOR), Barrios, C.H.3 (AUTHOR), Diéras, V.4 (AUTHOR), Iwata, H.5 (AUTHOR), Loi, S.6 (AUTHOR), Rugo, H.S.7 (AUTHOR), Schneeweiss, A.8 (AUTHOR), Winer, E.P.9 (AUTHOR), Patel, S.10,11 (AUTHOR), Henschel, V.12 (AUTHOR), Swat, A.13 (AUTHOR), Kaul, M.14 (AUTHOR), Molinero, L.15 (AUTHOR), Chui, S.Y.10 (AUTHOR), Schmid, P.16 (AUTHOR) |
| المصدر: | Annals of Oncology. Dec2021, Vol. 32 Issue 12, p1650-1650. 1p. |
| مصطلحات موضوعية: | *OVERALL survival, *TRIPLE-negative breast cancer, *ATEZOLIZUMAB, *SURVIVAL analysis (Biometry), *ONCOLOGY |
| قاعدة البيانات: | Academic Search Index |
Full Text Finder | تدمد: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2021.10.002 |